The Role of Pentraxin 3 and Cathepsin B Levels in Preeclamptic Pregnancy

Sanliurfa Mehmet Akif Inan Education and Research Hospital

Status

Completed

Conditions

Cathepsin B Level

Pre-Eclampsia

Pentraxin 3 Level

Treatments

Other: Cathepsin B and pentraxin 3 levels in preeclampsia with pregnant women

Study type

Observational

Funder types

Other

Identifiers

NCT05924061

2011-KAEK-25 2021/09-09

Details and patient eligibility

About

In this study, the investigator aim was to compare Cathepsin B and Pentraxin 3 levels measured from maternal serum of pregnant women diagnosed with preeclampsia in the second trimester, the effects of these levels on maternal/ fetal outcomes and the composite results of Cathepsin B and Pentraxin 3 levels alone or together and contribute to the literature in this area.

Full description

This prospective case-control study was conducted between 1 January 2022 and 31 December 2022 at Bursa Yuksek Ihtisas Training and Research Hospital. The study was conducted with pregnant women between ages of 18-45 who were diagnosed with preeclampsia in the second trimester. This study was conducted with total 156 pregnant women. participants were grouped according to the presence of preeclampsia; Group1: Patients diagnosed with preeclampsia between 20-28 weeks (study group) (n:78) , Group 2: Healthy pregnant women between 20-28 weeks without a diagnosis of preeclampsia ( control group) (n:78) . As soon as preeclampsia is diagnosed and before any treatment was started, maternal serum samples were collected in the Cathepsin B and Pentraxin 3 kit in amounts suitable for the study. The samples obtained were kept in biochemistry laboratory at -80 degrees until the study was conducted. After all samples were collected, Cathepsin B and Pentraxin 3 values were measured by ELISA method.

Enrollment

156 patients

Sex

Female

Ages

18 to 45 years old

Volunteers

Accepts Healthy Volunteers

Inclusion criteria

Singleton pregnancy
Pregnant women diagnosed with preeclampsia between 20-28 weeks of gestation
Healthy pregnant women between 20-28 weeks of gestation who want to be involved in the study.

Exclusion criteria

Multiple pregnancies
Pregnant women who gave birth below 24 weeks of gestation
Pregnant women diagnosed with other hypertensive diseases of pregnancy other than preeclampsia ( gestational hypertension, chronic hypertension, superimposed hypertension)
Pregnant women with chromosomal or congenital anomalies in the fetus
Women with a known infective or autoimmune disease before pregnancy